Published online Sep 25, 2023. doi: 10.5501/wjv.v12.i4.221
Peer-review started: June 27, 2023
First decision: July 19, 2023
Revised: August 2, 2023
Accepted: August 21, 2023
Article in press: August 21, 2023
Published online: September 25, 2023
Patients with chronic liver disease (CLD) may be at risk of adverse outcomes following coronavirus disease 2019 (COVID-19). Initial findings from Wuhan indicated potential liver injury in COVID-19 patients. With the growing role of obesity and alcohol, understanding the specific implications of alcohol-associated cirrhosis (AC) for patients with COVID-19 is of paramount clinical importance for prognostication and appropriate therapeutic strategy.
Cirrhosis is typically associated with immune system impairments, which might hinder the ability of patients to combat COVID-19. While several studies have indicated an increased risk of COVID-19 severity in cirrhotic patients, the specific impact of AC on inpatient outcomes remains incompletely defined.
This study primarily aims to assess the impact of AC on inpatient outcomes and mortality rates in patients hospitalized with COVID-19 compared to those without AC. Furthermore, we intend to identify predictors of mortality within the COVID-19 patient cohort with AC.
A retrospective cohort study was conducted using the National Inpatient Sample database 2020, focusing on hospitalizations with a primary diagnosis of COVID-19. Two cohorts were established based on the presence or absence of AC. Pro
Of the 738010 patients hospitalized with COVID-19 that fulfilled the selection criteria, 1325 with AC were compared to 1135 without AC. It was found that AC did not significantly increase mortality in COVID-19 patients. However, it was linked to a higher prevalence of inpatient complications, especially in certain demographics and those with higher Elix
AC does not increase mortality rates in the context of COVID-19 hospitalizations. However, it is associated with a heigh
This research provides valuable insights into the implications of AC for COVID-19 patients. It prompts clinicians to conduct future research and delve deeper into understanding the exact mechanisms leading to these complications in COVID-19 patients with AC. Exploring preventive measures or pharmacological treatment adjustments for this vulne